Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2011; 2:360-362. doi:10.7150/jca.2.360 This volume Cite

Short Report

Adoptive Cell Therapy for Patients with Melanoma

Mark E. Dudley✉

Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892-1201, USA

✉ Corresponding author: Mark Dudley, PhD. Surgery Branch, National Cancer Institute, NIH.

Citation:
Dudley ME. Adoptive Cell Therapy for Patients with Melanoma. J Cancer 2011; 2:360-362. doi:10.7150/jca.2.360. https://www.jcancer.org/v02p0360.htm
Other styles

File import instruction

Abstract

Adoptive cell therapy can be an effective treatment for some patients with advanced cancer. This report summarizes clinical trial results from the Surgery Branch, NCI, investigating tumor infiltrating lymphocytes (TIL) and gene engineered peripheral blood T cells for the therapy of patients with melanoma and other solid tumors.

Keywords: TIL, melanoma, NY-ESO-1, interleukin-2, lymphodepletion

Citation styles

APA
Dudley, M.E. (2011). Adoptive Cell Therapy for Patients with Melanoma. Journal of Cancer, 2, 360-362. https://doi.org/10.7150/jca.2.360.

ACS
Dudley, M.E. Adoptive Cell Therapy for Patients with Melanoma. J. Cancer 2011, 2, 360-362. DOI: 10.7150/jca.2.360.

NLM
Dudley ME. Adoptive Cell Therapy for Patients with Melanoma. J Cancer 2011; 2:360-362. doi:10.7150/jca.2.360. https://www.jcancer.org/v02p0360.htm

CSE
Dudley ME. 2011. Adoptive Cell Therapy for Patients with Melanoma. J Cancer. 2:360-362.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use